JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolmachev, V.
Right arrow Articles by Orlova, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolmachev, V.
Right arrow Articles by Orlova, A.

111In-Benzyl-DTPA–ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors

Vladimir Tolmachev1,2, Fredrik Y. Nilsson1,2, Charles Widström3, Karl Andersson1, Daniel Rosik2, Lars Gedda1, Anders Wennborg2 and Anna Orlova1,2

1 Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden; 2 Affibody AB, Bromma, Sweden; and 3 Department of Hospital Physics, Uppsala University Hospital, Uppsala, Sweden


Figure 1
View larger version (6K):

[in a new window]
  		FIGURE 1.  Amino acid sequence of ZHER2:342. HER2-binding site is formed by helices 1 and 2. Helix 3 provides structural rigidity of Affibody molecules.

 

Figure 2
View larger version (10K):

[in a new window]
  		FIGURE 2.  Cell-associated 111In radioactivity as function of time after interrupted incubation of SKOV-3 cells with 111In-benzyl-DTPA–ZHER2:342. Cell-associated radioactivity at time zero after interrupted incubation was considered as 100%. Data are presented as mean ± SD (n = 3). Error bars are not evident because they are smaller than • symbols.

 

Figure 3
View larger version (17K):

[in a new window]
  		FIGURE 3.  Specificity of 111In-benzyl-DTPA–ZHER2:342 uptake in vivo. One group of animals was preinjected with 375 µg ZHER2:342 to saturate HER2 receptors 1 h before injection of radiolabeled conjugate. All animals were injected with 1 µg 111In-benzyl-DTPA–ZHER2:342. Data are mean ± SD (n = 4).

 

Figure 4
View larger version (24K):

[in a new window]
  		FIGURE 4.  Tumor-to-organ ratio of 111In-benzyl-DTPA–ZHER2:342 in tumor-bearing nude mice. Ratios are calculated from animals of Table 1. Data are mean ± SD (n = 4).

 

Figure 5
View larger version (27K):

[in a new window]
  		FIGURE 5.  Imaging of HER2 expression in SKOV-3 xenografts in BALB/c nu/nu mice using 111In-benzyl-DTPA–ZHER2:342. Planar {gamma}-camera images were collected 4 h after administration of 111In-benzyl-DTPA–ZHER2:342. Tumors (arrows) were clearly visualized.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.